Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

GHADA A ABUSIN

Allopathic & Osteopathic Physicians Pediatrics Pediatric Hematology-Oncology

NPI
1992981435
CMS profile
818611
Location
ANN ARBOR, MI

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$86.06

1 record · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $86.06 1

By paying entity

PY2024 · entire year · sorted by reported total

Paying entityAmountRecords
VERTEX PHARMACEUTICALS INCORPORATED $86.06 1

Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

GHADA A ABUSIN

NPI 1992981435 · CMS profile ID 818611

Allopathic & Osteopathic Physicians / Pediatrics / Pediatric Hematology-Oncology

ANN ARBOR, MI

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1992981435?year=2024&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
GHADA A ABUSIN, NPI 1992981435, CMS profile ID 818611. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1992981435?year=2024&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). GHADA A ABUSIN, NPI 1992981435, CMS profile ID 818611. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1992981435?year=2024&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
GHADA A ABUSIN, NPI 1992981435, CMS profile ID 818611, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1992981435?year=2024&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

1 matching record · $86.06 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 1 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–1 of 1.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
VERTEX PHARMACEUTICALS INCORPORATED $86.0602/21/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1105923177 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $94.24 1
PY2021 $2,100.00 1
PY2022 $1,229.38 4
PY2023 $15.76 1
PY2024 $86.06 1
PY2025 $300.00 1

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $15,355.38 5
PY2024 Principal investigator $39,474.82 17
PY2023 Principal investigator $99,535.83 33
PY2022 Principal investigator $139,751.77 27
PY2021 Principal investigator $37,300.00 4
PY2019 Principal investigator $64,028.00 4

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

27 records in PY2022

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Global Blood Therapeutics, Inc. $2,300.00 11/25/2022 Covered Recipient Teaching Hospital
Univ Of Mi Hospitals & Hlth Ctrs
A Study of a Single Dose of Inclacumab to Reduce Re-admission in Participants With Sickle Cell Disease and Recurrent Vaso-occlusive Crises No dispute reported 06/30/2026 914606491
Principal investigator 1 Global Blood Therapeutics, Inc. $7,899.40 11/25/2022 Covered Recipient Teaching Hospital
Univ Of Mi Hospitals & Hlth Ctrs
A Study of a Single Dose of Inclacumab to Reduce Re-admission in Participants With Sickle Cell Disease and Recurrent Vaso-occlusive Crises No dispute reported 06/30/2026 914606497
Principal investigator 1 Global Blood Therapeutics, Inc. $2,000.00 11/23/2022 Covered Recipient Teaching Hospital
Univ Of Mi Hospitals & Hlth Ctrs
A Study of a Single Dose of Inclacumab to Reduce Re-admission in Participants With Sickle Cell Disease and Recurrent Vaso-occlusive Crises No dispute reported 06/30/2026 914606485
Principal investigator 1 National Marrow Donor Program $2,200.00 11/18/2022 Covered Recipient Teaching Hospital
Univ Of Mi Hospitals & Hlth Ctrs
Reduced Intensity Conditioning for Haploidentical Bone Marrow Transplantation in Patients with Symptomatic Sickle Cell Disease No dispute reported 06/30/2026 925798027
Principal investigator 1 Global Blood Therapeutics, Inc. $5,307.06 11/09/2022 Covered Recipient Teaching Hospital
Univ Of Mi Hospitals & Hlth Ctrs
A Study of a Single Dose of Inclacumab to Reduce Re-admission in Participants With Sickle Cell Disease and Recurrent Vaso-occlusive Crises No dispute reported 06/30/2026 914606479
Principal investigator 1 Global Blood Therapeutics, Inc. $6,000.00 09/01/2022 Covered Recipient Teaching Hospital
Univ Of Mi Hospitals & Hlth Ctrs
A Study of a Single Dose of Inclacumab to Reduce Re-admission in Participants With Sickle Cell Disease and Recurrent Vaso-occlusive Crises No dispute reported 06/30/2026 914606473
Principal investigator 1 Global Blood Therapeutics, Inc. $6,397.11 08/19/2022 Covered Recipient Teaching Hospital
Univ Of Mi Hospitals & Hlth Ctrs
A Study of a Single Dose of Inclacumab to Reduce Re-admission in Participants With Sickle Cell Disease and Recurrent Vaso-occlusive Crises No dispute reported 06/30/2026 914606467
Principal investigator 1 Global Blood Therapeutics, Inc. $6,000.00 08/05/2022 Covered Recipient Teaching Hospital
Univ Of Mi Hospitals & Hlth Ctrs
A Study of a Single Dose of Inclacumab to Reduce Re-admission in Participants With Sickle Cell Disease and Recurrent Vaso-occlusive Crises No dispute reported 06/30/2026 914606461
Principal investigator 1 Global Blood Therapeutics, Inc. $16,000.00 04/01/2022 Covered Recipient Teaching Hospital
Univ Of Mi Hospitals & Hlth Ctrs
A Study of a Single Dose of Inclacumab to Reduce Re-admission in Participants With Sickle Cell Disease and Recurrent Vaso-occlusive Crises No dispute reported 06/30/2026 914606503
Principal investigator 1 Global Blood Therapeutics, Inc. $4,000.00 04/01/2022 Covered Recipient Teaching Hospital
Univ Of Mi Hospitals & Hlth Ctrs
A Study of a Single Dose of Inclacumab to Reduce Re-admission in Participants With Sickle Cell Disease and Recurrent Vaso-occlusive Crises No dispute reported 06/30/2026 914606509
Principal investigator 1 Global Blood Therapeutics, Inc. $7,899.40 04/01/2022 Covered Recipient Teaching Hospital
Univ Of Mi Hospitals & Hlth Ctrs
A Study of a Single Dose of Inclacumab to Reduce Re-admission in Participants With Sickle Cell Disease and Recurrent Vaso-occlusive Crises No dispute reported 06/30/2026 914606515
Principal investigator 1 Global Blood Therapeutics, Inc. $2,300.00 04/01/2022 Covered Recipient Teaching Hospital
Univ Of Mi Hospitals & Hlth Ctrs
A Study of a Single Dose of Inclacumab to Reduce Re-admission in Participants With Sickle Cell Disease and Recurrent Vaso-occlusive Crises No dispute reported 06/30/2026 914606521
Principal investigator 1 Agios Pharmaceuticals, Inc. $10,200.00 03/30/2022 Covered Recipient Teaching Hospital
Univ Of Mi Hospitals & Hlth Ctrs
PyruvateKinase Deficiency Global Longitudinal Registry No dispute reported 06/30/2026 953534297
Principal investigator 1 Agios Pharmaceuticals, Inc. $3,800.00 03/30/2022 Covered Recipient Teaching Hospital
Univ Of Mi Hospitals & Hlth Ctrs
PyruvateKinase Deficiency Global Longitudinal Registry No dispute reported 06/30/2026 953534639
Principal investigator 1 Agios Pharmaceuticals, Inc. $4,544.00 03/30/2022 Covered Recipient Teaching Hospital
Univ Of Mi Hospitals & Hlth Ctrs
PyruvateKinase Deficiency Global Longitudinal Registry No dispute reported 06/30/2026 953536017
Principal investigator 1 Global Blood Therapeutics, Inc. $1,300.00 03/30/2022 Covered Recipient Teaching Hospital
Univ Of Mi Hospitals & Hlth Ctrs
To evaluate the safety and efficacy of inclacumab, a P-selectin inhibitor, in reducing the frequency of vaso-occlusive crises (VOCs) over one year in patients with sickle cell disease. No dispute reported 06/30/2026 914606533
Principal investigator 1 Agios Pharmaceuticals, Inc. $2,527.00 03/25/2022 Covered Recipient Teaching Hospital
Univ Of Mi Hospitals & Hlth Ctrs
PyruvateKinase Deficiency Global Longitudinal Registry No dispute reported 06/30/2026 953535021
Principal investigator 1 Agios Pharmaceuticals, Inc. $20,000.00 03/25/2022 Covered Recipient Teaching Hospital
Univ Of Mi Hospitals & Hlth Ctrs
PyruvateKinase Deficiency Global Longitudinal Registry No dispute reported 06/30/2026 953536273
Principal investigator 1 Global Blood Therapeutics, Inc. $129.00 03/25/2022 Covered Recipient Teaching Hospital
Univ Of Mi Hospitals & Hlth Ctrs
Open-label Ext Study to Eval the Long-term Safety of Inclacumab Administered to Participants with Sickle Cell Disease Who Have Participated in an Inclacumab Clinical Trial Primary objective of this study is to evaluate the long-term safety of every 12-wk dosing of inclacumab in participants with sickle cell disease (SCD)whohave completed a prior inclacumab clinical trial.Additional objectives areto evaluate the incidence of vaso-occlusive crises (VOCs), hospitalizations, missed work/schooldays No dispute reported 06/30/2026 914606539
Principal investigator 1 Global Blood Therapeutics, Inc. $3,250.00 03/25/2022 Covered Recipient Teaching Hospital
Univ Of Mi Hospitals & Hlth Ctrs
Open-label Ext Study to Eval the Long-term Safety of Inclacumab Administered to Participants with Sickle Cell Disease Who Have Participated in an Inclacumab Clinical Trial Primary objective of this study is to evaluate the long-term safety of every 12-wk dosing of inclacumab in participants with sickle cell disease (SCD)whohave completed a prior inclacumab clinical trial.Additional objectives areto evaluate the incidence of vaso-occlusive crises (VOCs), hospitalizations, missed work/schooldays No dispute reported 06/30/2026 914606543
Principal investigator 1 Global Blood Therapeutics, Inc. $1,300.00 03/18/2022 Non-covered Recipient Entity
ST JUDE CHILDRENS RESEARCH HOSPITAL INC
Open-label Ext Study to Eval the Long-term Safety of Inclacumab Administered to Participants with Sickle Cell Disease Who Have Participated in an Inclacumab Clinical Trial Primary objective of this study is to evaluate the long-term safety of every 12-wk dosing of inclacumab in participants with sickle cell disease (SCD)whohave completed a prior inclacumab clinical trial.Additional objectives areto evaluate the incidence of vaso-occlusive crises (VOCs), hospitalizations, missed work/schooldays No dispute reported 06/30/2026 914608109
Principal investigator 1 Global Blood Therapeutics, Inc. $5,500.00 03/16/2022 Covered Recipient Teaching Hospital
Univ Of Mi Hospitals & Hlth Ctrs
Open-label Ext Study to Eval the Long-term Safety of Inclacumab Administered to Participants with Sickle Cell Disease Who Have Participated in an Inclacumab Clinical Trial Primary objective of this study is to evaluate the long-term safety of every 12-wk dosing of inclacumab in participants with sickle cell disease (SCD)whohave completed a prior inclacumab clinical trial.Additional objectives areto evaluate the incidence of vaso-occlusive crises (VOCs), hospitalizations, missed work/schooldays No dispute reported 06/30/2026 914606527
Principal investigator 1 Global Blood Therapeutics, Inc. $2,399.40 02/16/2022 Non-covered Recipient Entity
NEW YORK CITY HEALTH AND HOSPITAL CORP
Open-label Ext Study to Eval the Long-term Safety of Inclacumab Administered to Participants with Sickle Cell Disease Who Have Participated in an Inclacumab Clinical Trial Primary objective of this study is to evaluate the long-term safety of every 12-wk dosing of inclacumab in participants with sickle cell disease (SCD)whohave completed a prior inclacumab clinical trial.Additional objectives areto evaluate the incidence of vaso-occlusive crises (VOCs), hospitalizations, missed work/schooldays No dispute reported 06/30/2026 914607793
Principal investigator 1 Global Blood Therapeutics, Inc. $6,300.00 02/11/2022 Non-covered Recipient Entity
NEW YORK CITY HEALTH AND HOSPITAL CORP
Open-label Ext Study to Eval the Long-term Safety of Inclacumab Administered to Participants with Sickle Cell Disease Who Have Participated in an Inclacumab Clinical Trial Primary objective of this study is to evaluate the long-term safety of every 12-wk dosing of inclacumab in participants with sickle cell disease (SCD)whohave completed a prior inclacumab clinical trial.Additional objectives areto evaluate the incidence of vaso-occlusive crises (VOCs), hospitalizations, missed work/schooldays No dispute reported 06/30/2026 914607799
Principal investigator 1 Global Blood Therapeutics, Inc. $2,399.40 02/09/2022 Covered Recipient Teaching Hospital
Univ Of Mi Hospitals & Hlth Ctrs
A Study of a Single Dose of Inclacumab to Reduce Re-admission in Participants With Sickle Cell Disease and Recurrent Vaso-occlusive Crises No dispute reported 06/30/2026 914606549
Principal investigator 1 Global Blood Therapeutics, Inc. $5,500.00 02/09/2022 Covered Recipient Teaching Hospital
Univ Of Mi Hospitals & Hlth Ctrs
A Study of a Single Dose of Inclacumab to Reduce Re-admission in Participants With Sickle Cell Disease and Recurrent Vaso-occlusive Crises No dispute reported 06/30/2026 914606555
Principal investigator 1 Global Blood Therapeutics, Inc. $2,300.00 01/28/2022 Non-covered Recipient Entity
DANA FARBER CANCER INSTITUTE INC
A Study of a Single Dose of Inclacumab to Reduce Re-admission in Participants With Sickle Cell Disease and Recurrent Vaso-occlusive Crises No dispute reported 06/30/2026 914607353